{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T18:00:47Z","timestamp":1790532047997,"version":"4.1.0"},"reference-count":78,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.ctrv.2020.102105","type":"journal-article","created":{"date-parts":[[2020,9,14]],"date-time":"2020-09-14T11:17:46Z","timestamp":1600082266000},"page":"102105","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":112,"special_numbering":"C","title":["EGFR exon 20 insertions in advanced non-small cell lung cancer: A new history begins"],"prefix":"10.1016","volume":"90","author":[{"given":"Jordi","family":"Remon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lizza E.L.","family":"Hendriks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andres F.","family":"Cardona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Besse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctrv.2020.102105_b0005","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1097\/JTO.0b013e3182779d18","article-title":"Natural history and molecular characteristics of lung cancers harboring EGFR exon 20 insertions","volume":"8","author":"Oxnard","year":"2013","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2020.102105_b0010","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1016\/j.jtho.2018.06.019","article-title":"Diverse EGFR Exon 20 insertions and co-occurring molecular alterations identified by comprehensive genomic profiling of NSCLC","volume":"13","author":"Riess","year":"2018","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2020.102105_b0015","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.lungcan.2018.10.007","article-title":"EGFR exon 20 insertion in lung adenocarcinomas among Hispanics (geno1.2-CLICaP)","volume":"125","author":"Cardona","year":"2018","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ctrv.2020.102105_b0020","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1158\/1535-7163.MCT-12-0620","article-title":"EGFR exon 20 insertion mutations in lung adenocarcinomas: prevalence, molecular heterogeneity, and clinicopathologic characteristics","volume":"12","author":"Arcila","year":"2013","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ctrv.2020.102105_b0025","first-page":"2892","article-title":"EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII)","volume":"5","author":"Midha","year":"2015","journal-title":"Am J Cancer Res"},{"issue":"Suppl 4","key":"10.1016\/j.ctrv.2020.102105_b0030","doi-asserted-by":"crossref","first-page":"S490","DOI":"10.1245\/s10434-013-3452-1","article-title":"Prevalence, clinicopathologic characteristics, and molecular associations of EGFR exon 20 insertion mutations in East Asian patients with lung adenocarcinoma","volume":"21","author":"Pan","year":"2014","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ctrv.2020.102105_b0035","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.lungcan.2007.06.024","article-title":"EGFR exon 20 insertion mutation in Japanese lung cancer","volume":"58","author":"Sasaki","year":"2007","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ctrv.2020.102105_b0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2020.03.014","article-title":"EGFR exon 20 insertion mutations in Chinese advanced non-small cell lung cancer patients: Molecular heterogeneity and treatment outcome from nationwide real-world study","author":"Yang","year":"2020","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ctrv.2020.102105_b0045","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2020.102105_b0050","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1016\/S1470-2045(19)30634-5","article-title":"Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"20","author":"Nakagawa","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2020.102105_b0055","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1016\/j.jtho.2018.07.001","article-title":"The incidence of brain metastases in stage IV ROS1-rearranged non-small cell lung cancer and rate of central nervous system progression on crizotinib","volume":"13","author":"Patil","year":"2018","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2020.102105_b0060","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1016\/j.jtho.2018.07.004","article-title":"Frequency of brain metastases and multikinase inhibitor outcomes in patients with RET-rearranged lung cancers","volume":"13","author":"Drilon","year":"2018","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2020.102105_b0065","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1093\/annonc\/mdx404","article-title":"Clinical and molecular characteristics of non-small-cell lung cancer (NSCLC) harboring EGFR mutation: results of the nationwide French Cooperative Thoracic Intergroup (IFCT) program","volume":"28","author":"Leduc","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2020.102105_b0070","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1093\/annonc\/mdt418","article-title":"Rare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10 117 patients: a multicentre observational study by the French ERMETIC-IFCT network","volume":"25","author":"Beau-Faller","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2020.102105_b0075","doi-asserted-by":"crossref","first-page":"e620","DOI":"10.1016\/j.cllc.2019.06.018","article-title":"Effectiveness of treatments for advanced non-small-cell lung cancer with exon 20 insertion epidermal growth factor receptor mutations","volume":"20","author":"Wu","year":"2019","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.ctrv.2020.102105_b0080","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41392-019-0038-9","article-title":"Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer","volume":"4","author":"Vyse","year":"2019","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.ctrv.2020.102105_b0085","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3007205","article-title":"Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer","author":"Yasuda","year":"20135216177","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.ctrv.2020.102105_b0090","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/s41591-018-0007-9","article-title":"Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer","volume":"24","author":"Robichaux","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.ctrv.2020.102105_b0095","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1002\/ijc.30047","article-title":"NSCLC harboring EGFR exon-20 insertions after the regulatory C-helix of kinase domain responds poorly to known EGFR inhibitors","volume":"139","author":"Yang","year":"2016","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ctrv.2020.102105_b0100","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.lungcan.2018.11.039","article-title":"Efficacy of afatinib or osimertinib plus cetuximab combination therapy for non-small-cell lung cancer with EGFR exon 20 insertion mutations","volume":"127","author":"Hasegawa","year":"2019","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ctrv.2020.102105_b0105","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.lungcan.2017.11.005","article-title":"A comprehensive review of uncommon EGFR mutations in patients with non-small cell lung cancer","volume":"114","author":"Tu","year":"2017","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ctrv.2020.102105_b0110","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/S1470-2045(15)00026-1","article-title":"Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6","volume":"16","author":"Yang","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2020.102105_b0115","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1038\/bjc.2016.372","article-title":"Non-classic EGFR mutations in a cohort of Dutch EGFR-mutated NSCLC patients and outcomes following EGFR-TKI treatment","volume":"115","author":"Kuiper","year":"2016","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ctrv.2020.102105_b0120","doi-asserted-by":"crossref","first-page":"3212","DOI":"10.1002\/cncr.29493","article-title":"Epidermal growth factor receptor exon 20 insertions in advanced lung adenocarcinomas: clinical outcomes and response to erlotinib","volume":"121","author":"Naidoo","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2020.102105_b0125","doi-asserted-by":"crossref","first-page":"e20593","DOI":"10.1200\/JCO.2019.37.15_suppl.e20593","article-title":"EGFR-A763_Y764insFQEA: a unique exon 20 insertion mutation that displays sensitivity to all classes of approved lung cancer EGFR tyrosine kinase inhibitors","volume":"37","author":"Gergis","year":"2019","journal-title":"JCO"},{"key":"10.1016\/j.ctrv.2020.102105_b0130","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1913662","article-title":"Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC","volume":"382","author":"Ramalingam","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2020.102105_b0135","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1200\/JCO.19.00931","article-title":"Osimertinib for patients with non-small-cell lung cancer harboring uncommon EGFR mutations: a multicenter, open-label, phase II trial (KCSG-LU15-09)","volume":"38","author":"Cho","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2020.102105_b0140","doi-asserted-by":"crossref","first-page":"38789","DOI":"10.18632\/oncotarget.5887","article-title":"In vitro modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant EGFR mutants in non-small-cell lung cancer","volume":"6","author":"Hirano","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.ctrv.2020.102105_b0145","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1158\/1535-7163.MCT-17-0758","article-title":"Antitumor activity of osimertinib, an irreversible mutant-selective EGFR tyrosine kinase inhibitor, in NSCLC harboring EGFR exon 20 insertions","volume":"17","author":"Floc\u2019h","year":"2018","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ctrv.2020.102105_b0150","doi-asserted-by":"crossref","unstructured":"Ji J, Aredo J, Piper-Valillo A, Huppert L et al. Osimertinib in non-small cell lung cancer (NSCLC) with atypical EGFR activating mutations: A retrospective multicenter study. J Clin Oncol 38: 2020 (Suppl; Abstr 9570) n.d. https:\/\/doi.org\/10.1200\/JCO.2020.38.15_suppl.9570.","DOI":"10.1200\/JCO.2020.38.15_suppl.9570"},{"key":"10.1016\/j.ctrv.2020.102105_b0155","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.lungcan.2019.12.013","article-title":"Osimertinib treatment for patients with EGFR exon 20 mutation positive non-small cell lung cancer","volume":"141","author":"van Veggel","year":"2020","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ctrv.2020.102105_b0160","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1186\/s12885-019-5820-0","article-title":"EGFR exon 20 insertion mutations and response to osimertinib in non-small-cell lung cancer","volume":"19","author":"Fang","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ctrv.2020.102105_b0165","doi-asserted-by":"crossref","unstructured":"Piotrowska Z, Wang Y, Sequist LV, Ramalingam S, et al. ECOG-ACRIN 5162: A phase II study of osimertinib 160 mg in NSCLC with EGFR exon 20 insertions. J Clin Oncol 38: 2020 (Suppl; Abstr 9513) n.d. https:\/\/doi.org\/10.1200\/JCO.2020.38.15_suppl.9513.","DOI":"10.1200\/JCO.2020.38.15_suppl.9513"},{"key":"10.1016\/j.ctrv.2020.102105_b0170","doi-asserted-by":"crossref","first-page":"e220","DOI":"10.1016\/j.jtho.2019.05.023","article-title":"Durable response of low-dose afatinib plus cetuximab in an adenocarcinoma patient with a novel EGFR Exon 20 insertion mutation","volume":"14","author":"Fang","year":"2019","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2020.102105_b0175","doi-asserted-by":"crossref","first-page":"e201","DOI":"10.1016\/j.jtho.2019.04.013","article-title":"A patient with EGFR Exon 20 insertion-mutant non-small cell lung cancer responded to osimertinib plus cetuximab combination therapy","volume":"14","author":"Fang","year":"2019","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2020.102105_b0180","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1200\/JCO.19.01488","article-title":"Gefitinib alone versus gefitinib plus chemotherapy for non-small-cell lung cancer with mutated epidermal growth factor receptor: NEJ009 study","volume":"38","author":"Hosomi","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2020.102105_b0185","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1200\/JCO.19.01154","article-title":"Gefitinib versus gefitinib plus pemetrexed and carboplatin chemotherapy in EGFR-mutated lung cancer","volume":"38","author":"Noronha","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2020.102105_b0190","doi-asserted-by":"crossref","first-page":"9007","DOI":"10.1200\/JCO.2018.36.15_suppl.9007","article-title":"Erlotinib plus bevacizumab (EB) versus erlotinib alone (E) as first-line treatment for advanced EGFR mutation\u2013positive non-squamous non\u2013small-cell lung cancer (NSCLC): Survival follow-up results of JO25567","volume":"36","author":"Yamamoto","year":"2018","journal-title":"JCO"},{"key":"10.1016\/j.ctrv.2020.102105_b0195","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdz260.002","article-title":"CTONG 1509: Phase III study of bevacizumab with or without erlotinib in untreated Chinese patients with advanced EGFR-mutated NSCLC","volume":"30","author":"Zhou","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2020.102105_b0200","doi-asserted-by":"crossref","first-page":"6548","DOI":"10.1158\/1078-0432.CCR-18-1541","article-title":"EGFR Exon 20 insertion mutations display sensitivity to hsp90 inhibition in preclinical models and lung adenocarcinomas","volume":"24","author":"Jorge","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2020.102105_b0205","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1093\/annonc\/mdy336","article-title":"Activity of the Hsp90 inhibitor luminespib among non-small-cell lung cancers harboring EGFR exon 20 insertions","volume":"29","author":"Piotrowska","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2020.102105_b0210","doi-asserted-by":"crossref","first-page":"835","DOI":"10.4143\/crt.2017.303","article-title":"Phase 1 studies of poziotinib, an irreversible pan-HER tyrosine kinase inhibitor in patients with advanced solid tumors","volume":"50","author":"Kim","year":"2018","journal-title":"Cancer Res Treat"},{"key":"10.1016\/j.ctrv.2020.102105_b0215","doi-asserted-by":"crossref","first-page":"S323","DOI":"10.1016\/j.jtho.2018.08.243","article-title":"A phase II trial of poziotinib in EGFR and HER2 exon 20 mutant non-small cell lung cancer (NSCLC)","volume":"13","author":"Heymach","year":"2018","journal-title":"J Thoracic Oncol"},{"key":"10.1016\/j.ctrv.2020.102105_b0220","doi-asserted-by":"crossref","unstructured":"Le X, Goldman JW, Clarke JM et al. Poziotinib shows activity and durability of responses in subgroups of previously treated EGFR exon 20 NSCLC patients. J Clin Oncol 38: 2020 (Suppl; Abstr 9514) n.d. https:\/\/doi.org\/10.1200\/JCO.2020.38.15_suppl.9514.","DOI":"10.1200\/JCO.2020.38.15_suppl.9514"},{"key":"10.1016\/j.ctrv.2020.102105_b0225","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/S1470-2045(16)30033-X","article-title":"Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial","volume":"17","author":"Park","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2020.102105_b0230","doi-asserted-by":"crossref","first-page":"3327","DOI":"10.1200\/JCO.2012.44.2806","article-title":"Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations","volume":"31","author":"Sequist","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2020.102105_b0235","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1016\/S1470-2045(17)30608-3","article-title":"Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial","volume":"18","author":"Wu","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2020.102105_b0240","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.2217\/fon-2019-0299","article-title":"Effects of dose modifications on the safety and efficacy of dacomitinib for EGFR mutation-positive non-small-cell lung cancer","volume":"15","author":"Corral","year":"2019","journal-title":"Future Oncol"},{"key":"10.1016\/j.ctrv.2020.102105_b0245","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1007\/s00432-019-02862-x","article-title":"First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): impact of afatinib dose adjustment and analysis of mode of initial progression for patients who continued treatment beyond progression","volume":"145","author":"Schuler","year":"2019","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.ctrv.2020.102105_b0250","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1093\/annonc\/mdw322","article-title":"Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma: post hoc analyses of the randomized LUX-Lung 3 and 6 trials","volume":"27","author":"Yang","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2020.102105_b0255","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.15_suppl.9007","article-title":"Antitumor activity of TAK-788 in NSCLC with EGFR exon 20 insertions","volume":"37","author":"Janne","year":"2019","journal-title":"JCO"},{"key":"10.1016\/j.ctrv.2020.102105_b0260","doi-asserted-by":"crossref","first-page":"S835","DOI":"10.1016\/j.jtho.2019.08.1801","article-title":"T790M or C797S confers acquired resistance to tarloxotinib and poziotinib in EGFR Exon 20 insertion-driven lung cancer models in vitro","volume":"14","author":"Suda","year":"2019","journal-title":"Journal of Thoracic Oncology"},{"key":"10.1016\/j.ctrv.2020.102105_b0265","doi-asserted-by":"crossref","first-page":"S282","DOI":"10.1016\/j.jtho.2019.08.567","article-title":"Identification of mechanisms of acquired resistance to poziotinib in EGFR Exon 20 mutant non-small cell lung cancer (NSCLC)","volume":"14","author":"Elamin","year":"2019","journal-title":"J Thoracic Oncol"},{"key":"10.1016\/j.ctrv.2020.102105_b0270","doi-asserted-by":"crossref","first-page":"S599","DOI":"10.1016\/j.jtho.2018.08.901","article-title":"Safety, PK, and preliminary antitumor Activity of the Oral EGFR\/HER2 Exon 20 inhibitor TAK-788 in NSCLC","volume":"13","author":"Neal","year":"2018","journal-title":"J Thoracic Oncol"},{"key":"10.1016\/j.ctrv.2020.102105_b0275","doi-asserted-by":"crossref","unstructured":"Horn L, Lin HM, Padda SK, Aggarwal Ch et al. Indirect comparison of TAK-788 vs real-world data outcomes in refractory non-small cell lung cancer (NSCLC) with EGFR exon 20 insertions. J Clin Oncol 38: 2020 (Suppl; Abstr 9580) n.d. https:\/\/doi.org\/10.1200\/JCO.2020.38.15_suppl.9580.","DOI":"10.1200\/JCO.2020.38.15_suppl.9580"},{"key":"10.1016\/j.ctrv.2020.102105_b0280","doi-asserted-by":"crossref","first-page":"3942","DOI":"10.1158\/0008-5472.CAN-15-2833","article-title":"A novel bispecific antibody targeting EGFR and cMet is effective against EGFR inhibitor-resistant lung tumors","volume":"76","author":"Moores","year":"2016","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2020.102105_b0285","doi-asserted-by":"crossref","DOI":"10.1158\/2159-8290.CD-20-0116","article-title":"Antitumor activity of amivantamab (JNJ-61186372), an EGFR-cMet bispecific antibody, in diverse models of EGFR Exon 20 insertion-driven NSCLC","author":"Yun","year":"2020","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ctrv.2020.102105_b0290","doi-asserted-by":"crossref","first-page":"S344","DOI":"10.1016\/j.jtho.2018.08.292","article-title":"A first-in-human phase 1 trial of the EGFR-cMET bispecific antibody JNJ-61186372 in patients with advanced non-small cell lung cancer (NSCLC)","volume":"13","author":"Park","year":"2018","journal-title":"J Thoracic Oncol"},{"key":"10.1016\/j.ctrv.2020.102105_b0295","doi-asserted-by":"crossref","first-page":"9009","DOI":"10.1200\/JCO.2019.37.15_suppl.9009","article-title":"JNJ-61186372 (JNJ-372), an EGFR-cMet bispecific antibody, in EGFR-driven advanced non-small cell lung cancer (NSCLC)","volume":"37","author":"Haura","year":"2019","journal-title":"JCO"},{"key":"10.1016\/j.ctrv.2020.102105_b0300","doi-asserted-by":"crossref","unstructured":"Park K, Johm T, Kim SW et al. Amivantamab (JNJ-61186372), an anti-EGFR-MET bispecific antibody, in patients with EGFR exon 20 insertion (exon20ins)-mutated non-small cell lung cancer (NSCLC). J Clin Oncol 38: 2020 (Suppl; Abstr 9512) n.d. https:\/\/doi.org\/10.1200\/JCO.2020.38.15_suppl.9512.","DOI":"10.1200\/JCO.2020.38.15_suppl.9512"},{"key":"10.1016\/j.ctrv.2020.102105_b0305","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1158\/1541-7786.MCR-19-0419","article-title":"TAS6417\/CLN-081 Is a Pan-mutation-selective EGFR tyrosine kinase inhibitor with a broad spectrum of preclinical activity against clinically relevant EGFR mutations","volume":"17","author":"Udagawa","year":"2019","journal-title":"Mol Cancer Res"},{"key":"10.1016\/j.ctrv.2020.102105_b0310","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1158\/1535-7163.MCT-17-1206","article-title":"TAS6417, a novel EGFR inhibitor targeting exon 20 insertion mutations","volume":"17","author":"Hasako","year":"2018","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ctrv.2020.102105_b0315","doi-asserted-by":"crossref","first-page":"A157","DOI":"10.1158\/1535-7163.TARG-17-A157","article-title":"Antitumor activity of tarloxotinib, a hypoxia-activated EGFR TKI, in patient-derived lung cancer cell lines harboring EGFR exon 20 insertions","volume":"17","author":"Estrada-Bernal","year":"2018","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ctrv.2020.102105_b0320","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1093\/annonc\/mdy542","article-title":"HER2 exon 20 insertions in non-small-cell lung cancer are sensitive to the irreversible pan-HER receptor tyrosine kinase inhibitor pyrotinib","volume":"30","author":"Wang","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2020.102105_b0325","doi-asserted-by":"crossref","first-page":"3081","DOI":"10.1158\/1538-7445.AM2019-3081","article-title":"DZD9008, an oral, wild type selective EGFR inhibitor for the treatment of non-small-cell lung cancer with Exon20 insertion and other activating mutations","volume":"79","author":"Xu","year":"2019","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2020.102105_b0330","doi-asserted-by":"crossref","unstructured":"Chen K, Pan G, Xu Y et al. Immune microenvironment features and efficacy of PD-1\/PD-L1 blockade in non-small cell lung cancer (NSCLC) patients with EGFR or HER2 exon 20 insertions. J Clin Oncol 38: 2020 (Suppl; Abstr E21540) n.d. https:\/\/doi.org\/10.1200\/JCO.2020.38.15_suppl.e21540.","DOI":"10.1200\/JCO.2020.38.15_suppl.e21540"},{"key":"10.1016\/j.ctrv.2020.102105_b0335","doi-asserted-by":"crossref","first-page":"S733","DOI":"10.1016\/j.jtho.2018.08.1233","article-title":"Driver mutations are associated with distinct patterns of response to immune checkpoint blockade in non-small cell lung cancer","volume":"13","author":"Negrao","year":"2018","journal-title":"J Thoracic Oncol"},{"key":"10.1016\/j.ctrv.2020.102105_b0340","doi-asserted-by":"crossref","first-page":"S422","DOI":"10.1016\/j.jtho.2018.08.474","article-title":"Efficacy and genomic correlates of response to anti-PD1\/PD-L1 blockade in non-small cell lung cancers harboring targetable oncogenes","volume":"13","author":"Vokes","year":"2018","journal-title":"J Thoracic Oncol"},{"issue":"Suppl; Abstr 9052","key":"10.1016\/j.ctrv.2020.102105_b0345","first-page":"n.d","article-title":"Association of EGFR and HER-2 exon 20 mutations with distinct patterns of response to immune checkpoint blockade in non-small cell lung cancer","volume":"36","author":"Negrao","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2020.102105_b0350","doi-asserted-by":"crossref","unstructured":"Reck M, Rodr\u00edguez-Abreu D, Robinson AG, Hui R, Cs\u0151szi T, F\u00fcl\u00f6p A, et al. Updated analysis of KEYNOTE-024: pembrolizumab versus platinum-based chemotherapy for advanced non-small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater. J Clin Oncol 2019:JCO1800149. https:\/\/doi.org\/10.1200\/JCO.18.00149.","DOI":"10.1200\/JCO.18.00149"},{"key":"10.1016\/j.ctrv.2020.102105_b0355","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1200\/JCO.19.03136","article-title":"Updated analysis from KEYNOTE-189: pembrolizumab or placebo plus pemetrexed and platinum for previously untreated metastatic nonsquamous non-small-cell lung cancer","volume":"38","author":"Gadgeel","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2020.102105_b0360","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(18)32409-7","article-title":"Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial","volume":"393","author":"Mok","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2020.102105_b0365","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/S1470-2045(19)30167-6","article-title":"Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial","volume":"20","author":"West","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2020.102105_b0370","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S2213-2600(19)30084-0","article-title":"Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial","volume":"7","author":"Reck","year":"2019","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.ctrv.2020.102105_b0375","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.18.00107","article-title":"Influence of TP53 mutation on survival in patients with advanced EGFR-mutant non\u2013small-cell lung cancer","author":"Aggarwal","year":"2018","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.ctrv.2020.102105_b0380","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1001\/jamaoncol.2017.4526","article-title":"EGFR-TKI-associated interstitial pneumonitis in nivolumab-treated patients with non-small cell lung cancer","volume":"4","author":"Oshima","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ctrv.2020.102105_b0385","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.jtho.2018.02.022","article-title":"Phase 1\/2 study of the safety and tolerability of nivolumab plus crizotinib for the first-line treatment of anaplastic lymphoma kinase translocation - positive advanced non-small cell lung cancer (CheckMate 370)","volume":"13","author":"Spigel","year":"2018","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2020.102105_b0390","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jtho.2018.09.001","article-title":"Increased Hepatotoxicity associated with sequential immune checkpoint inhibitor and crizotinib therapy in patients with non-small cell lung cancer","volume":"14","author":"Lin","year":"2019","journal-title":"J Thorac Oncol"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737220301432?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737220301432?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T09:24:14Z","timestamp":1759656254000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737220301432"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":78,"alternative-id":["S0305737220301432"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2020.102105","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"EGFR exon 20 insertions in advanced non-small cell lung cancer: A new history begins","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2020.102105","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102105"}}